AstraZeneca stock edges higher as new lung cancer license deal supports oncology pipeline
Published on 09/03/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca PLC stock (ISIN US6549022043) is trading slightly higher in early dealings on September 3, 2026, supported by a new global license agreement for the oral EGFR inhibitor Zegfrovy in lung cancer and a resilient oncology revenue base.
New lung cancer license adds to oncology momentum
According to a report from Pharmabiz dated September 3, 2026, AstraZeneca has completed a global license agreement for the oral EGFR inhibitor Zegfrovy for lung cancer, expanding its portfolio of targeted therapies in this indication.
Oncology remains AstraZeneca’s largest franchise, with oncology sales in the first half of 2026 reported at approximately USD 14.1 billion, up about 15 percent at constant exchange rates compared with the prior year period, according to recent analyst commentary summarizing the company’s latest half-year figures.
For investors, the key point is that the Zegfrovy license complements existing EGFR and broader lung cancer assets, reinforcing AstraZeneca’s strategy to grow oncology revenue faster than the rest of the business over the medium term.
Stock price and recent performance
On the New York Stock Exchange, AstraZeneca’s American depositary receipts traded at USD 161.74 at the close on September 2, 2026, with the shares down 0.45 percent on the day according to price data compiled by MarketBeat.
The same overview shows that AstraZeneca’s stock has declined 19.5 percent over the past six months and 11.7 percent year to date, underperforming its broader pharmaceutical industry benchmark, which has gained 13.0 percent in the same period.
In London, AstraZeneca PLC shares were recently quoted around 11,976.00 pence on September 3, 2026, with a relative strength index of 44.8 and nearby technical support around 11,460.00 pence, according to momentum analysis published by Journalarta.
Pipeline setbacks and analyst perspective
Despite the solid oncology growth, AstraZeneca’s share price has been weighed down by several recent clinical and pipeline setbacks that have triggered reassessments of future growth expectations.
Analyst commentary summarized by Yahoo Finance on September 2, 2026 notes that AstraZeneca’s stock fell about 19.5 percent over the past six months after a series of pipeline setbacks, even as underlying financial performance remained robust.
Those setbacks have led investors to scrutinize the balance between AstraZeneca’s late-stage pipeline risk and its current revenue streams, especially in oncology and cardiovascular, renal and metabolism, when considering the valuation at a market capitalization above USD 250 billion as indicated by recent stock portal data.
For retail investors, the combination of double-digit oncology growth and recent share price pressure makes AstraZeneca a case study in how pipeline news can overshadow otherwise solid reported figures over a six-month horizon.
Key product focus: Tagrisso in lung cancer
Within AstraZeneca’s lung cancer portfolio, the EGFR inhibitor Tagrisso remains a flagship product and a major contributor to oncology revenue, benefiting from recent late-stage trial readouts in non-small cell lung cancer reported by specialist media.
Recent coverage has highlighted that Tagrisso continues to post robust sales growth within the oncology segment, helping to support the 15 percent oncology revenue increase in the first half of 2026 compared with the prior year, even as other parts of the pipeline face setbacks.
AstraZeneca stock in the market context
As of September 2, 2026, AstraZeneca’s ADRs closed at USD 161.74 on the New York Stock Exchange, with extended trading quotes around USD 162.00 later that day, while London-listed shares traded near 11,976.00 pence on September 3, 2026.
These levels place the stock below recent peaks but above nearby technical support, reflecting a market that is balancing concerns over clinical trial risk with appreciation for the company’s expanding oncology franchise and strategic deals such as the Zegfrovy license agreement.
AstraZeneca at a glance
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: NYSE (ADR)
- Price (as of September 2, 2026, 15:59): 161.74 USD
- Market capitalization: 250.59 billion USD (as of September 2, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: FTSE 100
